[New hypoglycemic drugs in treatment of diabetes type 2].
Diabetes mellitus type 2 is a syndrome with different etiopathology and clinical picture. Results of clinical studies show that hyperglycaemia increases during the time of diabetes even if it is intensively treated. At the present time some new hypoglycaemic drugs have been introduced for type 2 diabetes mellitus therapy. These drugs can increase insulin secretion by the inhibition of the ATP-sensitive K+ channels (glimepyride, repaglinide) or by incretin action (glucagon-like peptide-1). Other drugs can decrease insulin resistance acting on nuclear receptors (troglitazone). Normalization of stomach motoric activity can also lead to decreasing of blood glucose concentration (pramlintid). Also other mechanisms of action are taken into consideration, like changing of cytokine activity or catabolism regulation of beta-cells of the Langerhans' islets.
Sokup
A
A
Katedra i Klinika Gastroenterologii i Chorób Wewnetrznych Akademii Medycznej im. Ludwika Rydygiera w Bydgoszczy.
Swiatkowski
M
M
D016207:Cytokines / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007333:Insulin Resistance; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism
D016207:Cytokines; D007004:Hypoglycemic Agents